Abstract: Objective To investigate the clinical values of atorvastatin combined with estrogen in the management of menopausal women with osteoporosis. Methods From January,2013 to November,2015,80 menopausal women with osteoporosis were enrolled in this prospective study.All patients were randomly signed into the experiment group or control group.The experiment group received the management of atorvastatin combined with estrogen while the control group received estrogen only.The primary outcomes included the level of estrogen,calcitonin,calcium,phosphorus,serum alkaline phosphatase,serum osteocalcin,and bone mineral density of femoral neck. Results There was no difference between the two groups in pre-treatment or post-treatment estrogen(P>0.05).No difference was observed in calcitonin before treatment[(191.18±49.12) vs. (210.23±58.16)pg/ml,P=0.118].However,when compared with the control group,patients in the experiment group got a significant higher level of calcitonin after the treatment[(262.10±72.50) pg/ml vs. (231.78±62.57) pg/ml,P=0.049)].There were no difference between the two groups in the level of calcium,phosphorus,serum alkaline phosphatase(P>0.05),and a significant difference was observed in serum osteocalcin when compared with the control group[(11.53±2.69)μg/L vs. (9.05±2.27)μg/L,P<0.001].There was no difference between the two groups in bone mineral density before treatment[(0.49±0.03)g/cm² vs. (0.48±0.04)g/cm²,P=0.174)] while a significant higher level of bone mineral density was observed in bone mineral density after the treatment[(0.54±0.03)g/cm² vs. (0.48±0.03)g/cm²,P=0.000]. Conclusion Atorvastatin combined with estrogen can increase the level of bone mineral density in menopausal women with osteoporosis.